Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel P Hermans

Showing results (21-30 of 122) with videos related to

Pageof 13
Sort By:
Journal of Diabetes and Its Complications|September 4, 2019
Increased CRP: An extended biomarker of microvascular risk in men with type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Cardiovascular Diabetology|March 12, 2014
Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipidsMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Current Atherosclerosis Reports|July 17, 2020
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib
Journal of Clinical & Translational Endocrinology|July 14, 2023
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetesFabian Lurquin, Sophie Gohy, Michel P Hermans, et al.
Journal of Diabetes and Its Complications|December 21, 2013
Parental brevity linked to cardiometabolic risk in diabetic descendantsMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Acta Cardiologica|March 24, 2020
Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelinesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Lipids in Health and Disease|September 14, 2017
The mixed benefit of low lipoprotein(a) in type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
European Journal of Clinical Investigation|January 10, 2012
eNOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Journal of Clinical and Translational Hepatology|September 18, 2023
A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes PatientsQuentin Binet, Audrey Loumaye, Michel P Hermans, et al.
Acta Diabetologica|November 7, 2013
What are the characteristics of phenotypic type 2 diabetic patients with low-titer GAD65 antibodies?Yovan P Mahadeb, Damien Gruson, Martin Buysschaert, et al.
Pageof 13

Showing results (21-30 of 122) with videos related to

Sort By:
Pageof 13
Journal of Diabetes and Its Complications|September 4, 2019
Increased CRP: An extended biomarker of microvascular risk in men with type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Cardiovascular Diabetology|March 12, 2014
Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipidsMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Current Atherosclerosis Reports|July 17, 2020
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib
Journal of Clinical & Translational Endocrinology|July 14, 2023
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetesFabian Lurquin, Sophie Gohy, Michel P Hermans, et al.
Journal of Diabetes and Its Complications|December 21, 2013
Parental brevity linked to cardiometabolic risk in diabetic descendantsMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Acta Cardiologica|March 24, 2020
Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelinesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Lipids in Health and Disease|September 14, 2017
The mixed benefit of low lipoprotein(a) in type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
European Journal of Clinical Investigation|January 10, 2012
eNOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Journal of Clinical and Translational Hepatology|September 18, 2023
A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes PatientsQuentin Binet, Audrey Loumaye, Michel P Hermans, et al.
Acta Diabetologica|November 7, 2013
What are the characteristics of phenotypic type 2 diabetic patients with low-titer GAD65 antibodies?Yovan P Mahadeb, Damien Gruson, Martin Buysschaert, et al.
Pageof 13